[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-check-hypertension-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-check-hypertension-screening":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100567629","evaluation-of-the-clinical-benefit-of-the-aktiia-blood-pressure-monitoring-for-early-awareness-of-hypertension-and-prediction-of-cardiovascular-risk-100567629",false,"NCT06670677","Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk","OBPM_FORESEE2024: Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk in a Multi-ethnic European Population: an Observational Cohorts' Study","FORESEE2024","Inclusion Criteria:\n\n1. Adult subjects aged 21 to 85 years old\n2. Subjects living in Switzerland, Germany or in the UK\n3. Subjects that are:\n\n   Aktiia users owning a smartphone with either iOS or Android operating system (ARMs 1 and 2); or Aktiia non-users owning a smartphone with iOS or Android operating system (ARM 3)\n4. Subjects agreeing to follow the study procedures.\n\nExclusion Criteria:\n\n1. Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including resting tachycardia (heart rate at rest \\> 120bpm) and atrial fibrillation;\n2. Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR \\\u003C 30mL \u002F min \u002F 1.73 m2), untreated hyper-\u002F hypothyroidism, pheochromocytoma, or arteriovenous fistula;\n3. Subjects suffering from polyneuropathy;\n4. on pregnant women;\n5. Subjects with damaged \u002F injured skin at the wrists (for bracelet measurements) or at index fingers (for camera measurements)\n6. Subjects with amputated index fingers (for camera measurements) or amputated upper limb;\n7. Subjects below 21 years old and above 85 years old.",true,"ALL","21 Years","85 Years",{"count":22,"type":23},15000,"ESTIMATED","OBSERVATIONAL","Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.",[27,28,29],"Hypertension","Cardiovascular Risk","Blood Pressure Check (Hypertension Screening)",[31,32,33,34,35,36],"hypertension","blood pressure","Hypertensive","cardiovascular diseases","cardiovascular risk","prediction","RECRUITING","2025-05-12",{"date":40,"type":41},"2025-05-14","ACTUAL",{"date":38,"type":41},{"date":44,"type":23},"2035-05-31",{"name":46,"class":47},"Aktiia SA","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100565894","effects-of-sleep-body-temperature-on-body-composition-100565894","NCT06648109","Effects of Sleep Body Temperature on Body Composition","Inclusion Criteria:\n\n\\- Participants aged 18-30 years, inclusive of both male and female genders.\n\nExclusion Criteria:\n\n* Individuals suffering from serious diseases such as heart, liver, kidney, brain, hematopoietic, immune, thyroid, malignant tumors, etc.;\n* Those with familial hereditary hypertension (both parents are hypertensive) or those diagnosed with hypertension;\n* Individuals with cognitive or mental impairments that prevent the completion of the questionnaire;\n* Persons with physical disabilities that hinder normal walking;\n* Persons who have experienced a weight change of \\>3.0 kg within 1 month or \\>10 kg within 6 months prior to screening (as per the study in Nutrients. 2020 Oct 21;12(10):3221);\n* Individuals required to take antibiotics from one week before the trial starts until its conclusion;\n* Those with habitual diarrhea or who have experienced diarrhea from one week before the trial starts until its end;\n* Subjects who have participated in other ambient temperature-related trials within the last 6 months;\n* Individuals with extreme sleep schedules (i.e., not falling asleep between 21:00 and 2:00 a.m. the following morning, or waking up before 5:00 a.m.);\n* Those with sleep latency (the time it takes to fall asleep after going to bed) greater than one hour;\n* Pittsburgh Sleep Quality Index (PSQI) scores greater than 16;\n* Participants who do not sign the informed consent form or are deemed unsuitable by the investigator for any other reason.","18 Years","30 Years",{"count":57,"type":23},40,"INTERVENTIONAL",[60],"NA","This will be a crossover controlled trial designed to recruit 40 participants, who will be divided into two groups of 20 subjects each. The participants will be randomly assigned to either Group A or Group B. Group A will receive the sleep electric blanket intervention for a period of 7 days, while Group B will serve as the control group without any additional intervention. After the intervention period, there will be a washout period of 7 days to ensure that any effects of the intervention have subsided before the crossover.\n\nFollowing the washout period, the groups will switch roles: Group B will then receive the sleep electric blanket intervention, and Group A will become the control group. This second phase will also last for 7 days, preceded and followed by the same assessment procedures as the initial phase. This design will allow for a comparison of the intervention's effects against a control period within the same group of participants, enhancing the study's internal validity.",[29,63,64],"Heart Rate","Aldosterone Disorder","NOT_YET_RECRUITING","2024-10-17",{"date":68,"type":41},"2024-10-18",{"date":70,"type":23},"2024-10-20",{"date":72,"type":23},"2025-01-30",{"name":74,"class":75},"Jinan University Guangzhou","OTHER",1]